GH Research Plc GHRS

Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Alignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results in postpartum depression published in The Journal of Clinical PsychiatryCash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026 DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming

GH Research stock has delivered strong gains over the past few years, yet its latest valuation checks suggest the shares may now be priced on the expensive side rather than offering clear value. Over the last 3 years, GH Research has returned 121.2% which puts the recent share price firmly in the spotlight for valuation focused investors. The key support for the current price can come from how investors view GH Research's ability to convert its research pipeline into sustainable cash flows,...

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.

Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.

GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (NASDAQ:ATAI), a development that sparked renewed investor interest across the sector. Potential acquisition lifts sentiment across psychedelic drug developersThe reported takeover talks sent Atai shares soaring by as much as 53% before the opening bell, with investors speculating that increased pha

An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc....

GH Research PLC (NASDAQ:GHRS) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 19, 2026, H.C. Wainwright lowered the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $65 from $70 and maintained a Buy rating on the shares. H.C. Wainwright cited share count dilution from the company’s April […]

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial,” has been published in The Journal of Clinical Psychiatry (D

Key Takeaways; Cannabis Sector Organigram Reported its Second Quarter Fiscal 2026 Financial Results Village Farms Reported Q1 2026 Results Driven by Record International Export Sales Cronos Group Reported 2026 First Quarter Financial Results Key Takeaways; Psychedelic Sector GH Research Reported First Quarter 2026 Financial Results and Provided Business Update Definium Therapeutics Announced First Patient had […]

GH Research (NasdaqGM:GHRS) has drawn fresh attention after publishing Phase 2b results for its lead depression treatment in JAMA Psychiatry, advancing Phase 1 programs and outlining a global Phase 3 plan, while reporting a sizeable cash position. See our latest analysis for GH Research. Those clinical updates and fresh financing plans sit against a share price of US$21.39, with a 30-day share price return of 20.57% and a 90-day share price return of 45.51%. The 1-year total shareholder...

Phase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study enrolment completedCash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharma

DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and off